Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.

Sari S., Yilmaz M. T., Aktas B. Y., Aksoy S., Gullu I., Cengiz M., ...More

Oral oncology, vol.124, pp.105658, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 124
  • Publication Date: 2022
  • Doi Number: 10.1016/j.oraloncology.2021.105658
  • Journal Name: Oral oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.105658
  • Keywords: Head and neck cancer, Immunotherapy, Nivolumab, Radiotherapy, Re-irradiation, SBRT, SQUAMOUS-CELL CARCINOMA, SALVAGE SURGERY, OPEN-LABEL, REIRRADIATION, CHEMOTHERAPY, PEMBROLIZUMAB, TRIAL, RADIATION, CETUXIMAB, CRITERIA
  • Hacettepe University Affiliated: Yes

Abstract

Objectives: In metastatic and recurrent head and neck cancer (M/R HN-SCC), the median survival is less than a year and locoregional recurrence is the main cause of death. Our aim was to evaluate the results of concurrent stereotactic body radiotherapy (SBRT) and immunotherapy (ICI) in these patients. Materials and methods: Fifteen patients diagnosed with M/R HN-SCC were evaluated retrospectively. All patients received SBRT (3x8 Gy) to all recurrent and metastatic foci with concurrent ICI. Results: Six months overall survival (OS) rates and progression-free survival (PFS) rates were 93% and 86%, respectively. Local control (LC) rate in the site of SBRT was 96%. Higher survival and LC rates were achieved with lower doses of radiotherapy with the synergistic effect of SBRT and ICI. Conclusion: Concurrent ICI and SBRT was feasible with excellent LC.